製品名:4-Amino-2-hydroxy-5-methylpyridine

IUPAC Name:4-amino-5-methyl-1,2-dihydropyridin-2-one

CAS番号:95306-64-2
分子式:C6H8N2O
純度:98%
カタログ番号:CM120752
分子量:124.14

包装単位 有効在庫 価格(USD) 数量
CM120752-100g in stock ǠdžȤ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:95306-64-2
分子式:C6H8N2O
融点:-
SMILESコード:O=C1C=C(N)C(=CN1)C
密度:
カタログ番号:CM120752
分子量:124.14
沸点:
MDL番号:MFCD18384902
保管方法:Keep in dark place, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Finerenone
Bayer announced that FINEARTS-HF met its primary endpoint, achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits. The randomized, double-blind, placebo-controlled, parallel-group, multi-center phase III cardiovascular outcomes study evaluated the efficacy and safety of KERENDIA® (finerenone) for investigational new use in patients with HF with a LVEF≥40% (left ventricular ejection fraction). Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with CKD associated with T2D.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.